Agios Pharmaceuticals Inc (AGIO) Draws Bullish Attention After Forming Wedge Up Chart Pattern

September 17, 2017 - By Stephen Andrade

Investors sentiment decreased to 1.1 in Q4 2016. Its down 0.62, from 1.72 in 2016Q3. It is negative, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported.
Profund Advisors Ltd Liability Corp has 0.03% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 14,443 shares. Paradigm Asset Mngmt Ltd Llc invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,638 shares. 1,071 were reported by Manufacturers Life The. Rhumbline Advisers invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). 29 were reported by Sei Investments. Bnp Paribas Invest Prtn Sa holds 0.05% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 131,945 shares. Fincl Bank Of Montreal Can owns 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 1,852 shares. Artal Grp has invested 0.69% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Tiaa Cref Inv reported 93,697 shares stake. 123,303 were accumulated by Aqr Capital Mngmt Lc. Blackrock Group Ltd owns 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 104,407 shares. Federated Investors Pa holds 0% or 7,519 shares in its portfolio. Valley National Advisers owns 157 shares for 0% of their portfolio. Jpmorgan Chase & has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Since March 20, 2017, it had 0 buys, and 7 selling transactions for $906,379 activity. Schenkein David P sold $175,860 worth of stock. $101,730 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Cantley Lewis Clayton Jr. on Tuesday, June 13. 6,438 Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares with value of $354,090 were sold by Biller Scott.

The stock of Agios Pharmaceuticals Inc (AGIO) formed an up wedge with $71.74 target or 8.00 % above today’s $66.43 share price. The 5 months wedge indicates low risk for the $3.21B company. If the $71.74 price target is reached, the company will be worth $256.80 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 1.28% or $0.84 on September 15, reaching $66.43. About 863,491 shares traded or 99.81% up from the average. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since September 17, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report $-1.74 EPS on November, 2.They anticipate $0.11 EPS change or 6.75 % from last quarter’s $-1.63 EPS. After having $-1.78 EPS previously, Agios Pharmaceuticals Inc’s analysts see -2.25 % EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 15 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Agios Pharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Roth Capital given on Monday, November 9. The firm earned “Overweight” rating on Monday, June 13 by JP Morgan. The stock has “Buy” rating by Cowen & Co on Tuesday, June 6. Leerink Swann upgraded the shares of AGIO in report on Wednesday, August 2 to “Outperform” rating. The company was initiated on Friday, August 19 by BTIG Research. The company was maintained on Tuesday, August 8 by Oppenheimer. The firm has “Buy” rating by Cowen & Co given on Tuesday, August 8. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Market Perform” rating given on Monday, December 7 by Leerink Swann. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, August 5 with “Hold” rating. Credit Suisse maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, May 18 with “Outperform” rating.

More news for Agios Pharmaceuticals Inc (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Agios: Smooth First Mover In Cancer Metabolism” on August 08, 2017. Seekingalpha.com‘s article titled: “Agios, Amigos!” and published on May 26, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.